AirSculpt Technologies, Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request references 2022 Q4, this is an annual filing, not a standalone quarterly report. The company provides premium, self-pay body-contouring procedures under the Elite Body Sculpture brand, primarily using its AirSculpt method. Its affiliated professional associations deliver clinical services; the company provides non-clinical management services. Financial statements consolidate those entities.
Key financial and operating metrics
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $168.8 million | $133.3 million |
| Cases performed | 13,063 | 11,050 |
| Revenue per case | $12,922 | $12,065 |
| Cost of service / revenue | 37.2% | 33.4% |
| SG&A / revenue | 60.1% | 49.3% |
| Operating income (loss) | $(4.5) million | $15.8 million |
| Net income (loss) | $(14.7) million | $10.6 million |
| Adjusted EBITDA (non-GAAP) | $43.2 million; 25.6% margin | $46.1 million; 34.6% margin |
| Cash from operating activities | $24.4 million | $26.6 million |
| Cash and cash equivalents at year-end | $9.6 million | $25.3 million |
| Term debt principal at year-end | $85.0 million | $84.3 million |
Revenue rose 26.6%. Cases increased 18.2%, while revenue per case rose 7.1%. However, at comparable centers, case volume grew only 0.7%; same-center revenue per case increased 7.4%. Management attributed higher revenue per case in part to patients treating more areas per visit.
GAAP profitability weakened materially: operating margin fell to negative 2.7% from 11.8%, and net margin to negative 8.7% from positive 7.9%. SG&A increased 54.3%, including a $22.3 million increase in equity-based compensation and approximately $6.7 million in incremental public-company costs. Equity-based compensation expense was $29.5 million. Adjusted EBITDA declined year over year; management said that excluding the incremental public-company costs in 2022, adjusted EBITDA increased $3.7 million, or 9.4%. Adjusted net income was $21.7 million, or $0.37 per diluted share, both non-GAAP measures.
Operating cash flow was $24.4 million; capital expenditures were $12.9 million, leaving approximately $11.5 million of operating cash flow after those expenditures. Financing activities used $27.3 million, including $23.2 million of cash dividends. The company reported negative working capital of $5.6 million, compared with positive working capital of $13.0 million a year earlier; it attributed the decline primarily to the dividend.
Year-end debt included $85.0 million of variable-rate term loans and an undrawn $5.0 million revolver. The credit agreement matures in November 2027 and is secured by substantially all company assets. The filing reports covenant compliance at year-end. Scheduled principal maturities include $70.1 million in 2027. Management estimated that a 100-basis-point rate change would affect annual interest expense by approximately $0.9 million. Cash was $9.6 million at year-end.
Material changes and notable items
- Four new centers were added in 2022, bringing the footprint to 22 centers as of March 10, 2023; the company also expanded procedure-room capacity. New centers and rooms are still ramping, and management said cases per procedure room declined temporarily as capacity expanded.
- Cost of service rose faster than revenue, partly because newer centers generally have higher costs as a share of revenue while they mature, and because of investment in clinical staffing.
- The company refinanced its credit facility in November 2022, recognizing a $0.9 million debt-modification loss. It also paid a special cash dividend of $0.41 per share, totaling $23.2 million.
- AirSculpt+ and AirSculpt Smooth were introduced in 2022. The company performed 13,063 procedures during the year and reported average revenue per case of $12,922.
- Founder Aaron Rollins moved from CEO to Executive Chairman; Todd Magazine became CEO in January 2023. COO and President Ronald Zelhof’s employment ended in December 2022.
Outlook, risks and contingencies
The filing gives no formal FY 2023 revenue or earnings guidance. Management’s stated strategy is to target three to four new centers annually, increase capacity and utilization at existing centers, develop new procedures, and continue marketing investment. Management said cash from operations and revolver availability should meet anticipated working-capital, expansion, capital-expenditure and debt-payment needs for at least 12 months.
Key risks include the discretionary nature of procedures and sensitivity to consumer confidence, inflation and interest rates; reliance on patient financing (approximately 43% of 2022 cases used third-party financing); competition for surgeons and staff; and dependence on a single manufacturer for the AirSculpt handpiece, without a qualified alternate supplier. The company also highlights medical-liability exposure, evolving corporate-practice-of-medicine and fee-splitting rules, healthcare regulation, privacy and cybersecurity risks, and risks from international expansion. California generated 20% of 2022 revenue.
The company said current legal matters are routine and are not expected to have a material adverse effect, while noting outcomes cannot be assured and insurance may be inadequate. The auditor issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting as of year-end; the auditor was not engaged to express an opinion on internal-control effectiveness.
Important facts for investors to verify
- Whether growth is being sustained by underlying comparable-center demand: same-center case growth was only 0.7%, while revenue per case rose 7.4%.
- Whether operating margins and cash generation improve as new centers mature, particularly given higher service costs and substantial equity-based compensation.
- Liquidity and debt-service capacity, including variable-rate exposure, covenant requirements, and the large scheduled 2027 principal maturity.
- The impact of continued center expansion and the planned three-to-four annual openings on capital needs, staffing, and returns.
- Exposure to consumer-credit availability, clinical claims, healthcare-law changes, and the single-source handpiece supplier.
- The assumptions and exclusions behind non-GAAP Adjusted EBITDA and adjusted net income; these measures exclude significant items and do not replace GAAP results or cash-flow analysis.